As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share.
Japan’s Takeda is making a big push with a vaccine for dengue and says to be prepared it will build a €100 million plant at its manufacturing site in Singen,…
GSK is setting out for European approval for Shingrix, which analysts think might be able to hit blockbuster sales in the coming years.
Bavarian Nordic is closer to the finish line in the U.S. with its smallpox vaccine Imvamune.
An editorial in The BMJ argues that the global health community shouldn't continue to rely on "random acts of charity" in vaccine pricing.
Seeking to deliver the “final nail in the coffin for HIV,” NIH scientists have kicked off a large clinical trial of a vaccine regimen this week in South Africa.
Themis closed a second round of financing worth €10 million, which will be used for its Chikungunya vaccine and to further a Zika-fighting candidate.
A team of scientists from Australia is making progress in developing a vaccine that protects the human “surfaces” most likely to encounter the virus first.
The World Health Organization is no longer calling the Zika outbreak an international emergency, maintaining that the fight will continue to require “intense…
Though cancer vaccines have experienced disappointing clinical performance in recent years, their global market as a crucial tool in immunotherapy will grow to…